Profile of patients undergoing treatment with long-acting injectable antipsychotic drugs in a psychiatry hospital in Portugal

Introduction The treatment with long-acting injectable antipsychotics (LAIAs) is more and more frequent and it shows advantages regarding adherence, effectiveness and tolerance. Objectives To describe and compare the profile of patients under treatment with LAIAs in a psychiatric hospital in Portug...

Full description

Bibliographic Details
Main Authors:	J. R. P. Correia, R. A. Moreira, E. Maldonado, H. J. Gomes, J. R. Gomes
Format:	Article
Language:	English
Published:	Cambridge University Press 2023-03-01
Series:	European Psychiatry
Online Access:	https://www.cambridge.org/core/product/identifier/S092493382300336X/type/journal_article

Similar Items

Long acting injectable antipsychotics – Where are we?
by: Phani Prasant Mulakaluri
Published: (2015-01-01)

Prescribing practice of long-acting injectable antipsychotics
by: Jisha M Lucca, et al.
Published: (2020-01-01)

Second Generation Long-Acting Injectable Antipsychotics in Africa: About a Case
by: J. Galvañ, et al.
Published: (2023-03-01)

Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile
by: Zolezzi M, et al.
Published: (2021-06-01)

The Use of Long-Acting Injectable Antipsychotic Therapy for Schizophrenia
by: Jason Jiang, et al.
Published: (2018-09-01)

Long-acting injectable antipsychotics during pregnancy: An update
by: A. Paraschakis, et al.
Published: (2021-04-01)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
by: John M. Kane, et al.
Published: (2023-03-01)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
by: JP Lindenmayer
Published: (2010-05-01)

The use of long-acting injectable antipsychotics in an acute psychiatric unit
by: G. Ortega-Hernández, et al.
Published: (2023-03-01)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
by: Heidi J. Wehring, et al.
Published: (2011-06-01)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
by: Heidi J. Wehring, et al.
Published: (2011-01-01)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
by: Milz R, et al.
Published: (2023-03-01)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
by: David D. Kim, et al.
Published: (2021-07-01)

Knowledge about antipsychotic long-acting injections: bridging that gap
by: Burns, T
Published: (2009)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
by: Francisco José Toja-Camba, et al.
Published: (2021-06-01)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
by: Patel, R, et al.
Published: (2017)

The evolution of antipsychotic medication: a long-acting injectable formulation of a second-generation antipsychotic
by: Piet Oosthuizen
Published: (2006-06-01)

Analysis of adverse drug reactions of atypical antipsychotic drugs in psychiatry OPD
by: Kiran G Piparva, et al.
Published: (2011-01-01)

Assessment of oral overlap with antipsychotic long-acting injectables initiated in an inpatient setting
by: Tran Jennifer T. PharmD, et al.
Published: (2023-06-01)

Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics
by: Ching-Hua Lin, et al.
Published: (2022-03-01)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
by: Shubhra Mace, et al.
Published: (2019-07-01)

Expert Consensus on Long-acting Injectable Antipsychotic in the Treatment of Schizophrenia in Community
by: Chinese Schizophrenia Coordination Group, Chinese Society of Psychiatry, Chinese Society of General Practice
Published: (2022-10-01)

Long-Acting Injectable Antipsychotics—A Review on Formulation and In Vitro Dissolution
by: Magdalena Markowicz-Piasecka, et al.
Published: (2023-12-01)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
by: O. Vasiliu
Published: (2022-06-01)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
by: Riboldi I, et al.
Published: (2022-12-01)

Attitudes of European physicians towards the use of long-acting injectable antipsychotics
by: Maxine X. Patel, et al.
Published: (2020-03-01)

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
by: Petru Ifteni, et al.
Published: (2021-12-01)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
by: Leslie Citrome
Published: (2009-11-01)

Treatment effectiveness of shifting from risperidone long-acting injectable to first-generation long-acting injectable antipsychotics in patients with schizophrenia
by: Ching- Yin Chang, et al.
Published: (2019-01-01)

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
by: Hýža M, et al.
Published: (2021-04-01)

Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
by: Antonio Ventriglio, et al.
Published: (2019-01-01)

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
by: Kaplan G, et al.
Published: (2013-11-01)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
by: Suda A, et al.
Published: (2018-09-01)

Preliminary results of a network meta-analysis on the efficacy of long-acting injectable antipsychotics in schizophrenia
by: R. Medrano, et al.
Published: (2021-04-01)

Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary.
by: P Takács, et al.
Published: (2019-01-01)

Effect of Transition to Long-acting Injectable Antipsychotic Treatment on Care Burden in Schizophrenia
by: Elif Özcan Tozoğlu, et al.
Published: (2021-12-01)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
by: M.F. Tascón Guerra, et al.
Published: (2022-06-01)

Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
by: Lulu Lian, et al.
Published: (2022-01-01)

Why we should use long-acting injectable antipsychotics more frequently
by: João Paulo Maia-de-Oliveira, et al.
Published: (2013-09-01)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
by: Chiu LL, et al.
Published: (2019-07-01)